MarketCap
Aligos Therapeutics ALGS
$ 2.59
-35.25%
Facebook
X
Telegram
Aligos Therapeutics ROA Ratio | ALGS
Annual ROA Ratio Aligos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.33 | -187.19 | -57.86 | -65.47 | -54.52 | -40.91 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.33 | -187.19 | -72.22 |
Quarterly ROA Ratio Aligos Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -106.74 | -89.14 | -98.65 | -34.37 | -129.12 | -122.16 | -105.74 | -161.59 | -62.79 | -62.03 | -84.38 | -75.98 | -72.5 | -62.83 | -56.04 | -54.11 | -55.21 | -56.45 | -59.61 | -54.49 | -51.44 | -74.97 | -68.73 | -64.48 | -61.1 | -7.84 | -7.55 | - | -9.59 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.55 | -161.59 | -69.63 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Fate Therapeutics
FATE
|
-42.74 | $ 1.78 | -8.51 % | $ 211 M |  USA |
 |
Greenwich LifeSciences
GLSI
|
-313.34 | $ 16.05 | -2.85 % | $ 217 M | USA |
 |
Halozyme Therapeutics
HALO
|
12.55 | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
26.06 | $ 15.34 | 0.1 % | $ 13.2 B |  China |
 |
Aptorum Group Limited
APM
|
-7.29 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-33.13 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
-65.42 | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-180.82 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
BioAtla
BCAB
|
-431.06 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-76.57 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
5.95 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
ARCA biopharma
ABIO
|
-21.58 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-11.69 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-260.96 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
-28406.21 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-63.73 | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
-254.8 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-56.78 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.34 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-93.47 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
36.63 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-117.88 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-44.15 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-35.83 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
1.93 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-87.54 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
153.4 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
48.24 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.85 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-103.31 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-80.54 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
0.06 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-217.5 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-34.54 | - | 1.35 % | $ 17.8 M | China |